よむ、つかう、まなぶ。
10参考資料１－２ 成人用肺炎球菌ワクチンファクトシート［4.9MB］ (38 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_70339.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第64回 2／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
67.
McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T. Acute bacterial meningitis in adults.
Lancet 2016; 388(10063): 3036-47.
68.
Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal
vaccination. Lancet 2011; 378(9807): 1962-73.
69.
Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the
era of conjugate vaccine. J Infect Dis 2010; 201(1): 32-41.
70.
Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing
invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One 2017;
12(5): e0177113.
71.
Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4
years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort
study. Lancet Infect Dis 2011; 11(10): 760-8.
72.
Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive
pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
Lancet Infect Dis 2018; 18(4): 441-51.
73.
Chiba N, Morozumi M, Sunaoshi K, et al. Serotype and antibiotic resistance of isolates from patients
with invasive pneumococcal disease in Japan. Epidemiol Infect 2010; 138(1): 61-8.
74.
Tamura K, Chang B, Shimbashi R, et al. Dynamic changes in clinical characteristics and serotype
distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13valent pneumococcal conjugate vaccine in 2013-2019. Vaccine 2022; 40(24): 3338-44.
75.
Chang B, Tamura K, Fujikura H, et al. Pneumococcal meningitis in adults in 2014-2018 after
introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan. Sci Rep 2022; 12(1): 3066.
76.
El Safadi D, Hitchins L, Howard A, et al. Pneumococcal Carriage and Disease in Adults in England,
2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities. J Infect Dis 2025;
231(1): e17-e27.
77.
厚生労働省. 令和 5 年患者調査の概況. 2024.
https://www.mhlw.go.jp/toukei/saikin/hw/kanja/23/dl/kanjya.pdf (accessed 2025/03/06).
78.
厚生労働省. 平成 26 年患者調査の概況. 2014. https://www.mhlw.go.jp/toukei/saikin/hw/kanja/14/
(accessed 2025/03/06).
79.
厚生労働省. 平成 29 年患者調査の概況. 2017.
https://www.mhlw.go.jp/toukei/saikin/hw/kanja/17/index.html (accessed 2025/03/06).
80.
厚生労働省. 令和 2 年患者調査の概況. 2020.
https://www.mhlw.go.jp/toukei/saikin/hw/kanja/20/index.html (accessed 2025/03/06).
81.
Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in
the aging Japanese population: a multicenter prospective study. PLoS One 2015; 10(3): e0122247.
82.
Miyazaki T, Hirano K, Ichihara K, et al. Community-Acquired Pneumonia Incidence in Adults Aged
18 Years and Older in Goto City, Japan: A Prospective Population-Based Study. CHEST Pulmonary 2023;
1(2).
38
McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T. Acute bacterial meningitis in adults.
Lancet 2016; 388(10063): 3036-47.
68.
Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal
vaccination. Lancet 2011; 378(9807): 1962-73.
69.
Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the
era of conjugate vaccine. J Infect Dis 2010; 201(1): 32-41.
70.
Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing
invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One 2017;
12(5): e0177113.
71.
Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4
years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort
study. Lancet Infect Dis 2011; 11(10): 760-8.
72.
Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive
pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
Lancet Infect Dis 2018; 18(4): 441-51.
73.
Chiba N, Morozumi M, Sunaoshi K, et al. Serotype and antibiotic resistance of isolates from patients
with invasive pneumococcal disease in Japan. Epidemiol Infect 2010; 138(1): 61-8.
74.
Tamura K, Chang B, Shimbashi R, et al. Dynamic changes in clinical characteristics and serotype
distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13valent pneumococcal conjugate vaccine in 2013-2019. Vaccine 2022; 40(24): 3338-44.
75.
Chang B, Tamura K, Fujikura H, et al. Pneumococcal meningitis in adults in 2014-2018 after
introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan. Sci Rep 2022; 12(1): 3066.
76.
El Safadi D, Hitchins L, Howard A, et al. Pneumococcal Carriage and Disease in Adults in England,
2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities. J Infect Dis 2025;
231(1): e17-e27.
77.
厚生労働省. 令和 5 年患者調査の概況. 2024.
https://www.mhlw.go.jp/toukei/saikin/hw/kanja/23/dl/kanjya.pdf (accessed 2025/03/06).
78.
厚生労働省. 平成 26 年患者調査の概況. 2014. https://www.mhlw.go.jp/toukei/saikin/hw/kanja/14/
(accessed 2025/03/06).
79.
厚生労働省. 平成 29 年患者調査の概況. 2017.
https://www.mhlw.go.jp/toukei/saikin/hw/kanja/17/index.html (accessed 2025/03/06).
80.
厚生労働省. 令和 2 年患者調査の概況. 2020.
https://www.mhlw.go.jp/toukei/saikin/hw/kanja/20/index.html (accessed 2025/03/06).
81.
Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in
the aging Japanese population: a multicenter prospective study. PLoS One 2015; 10(3): e0122247.
82.
Miyazaki T, Hirano K, Ichihara K, et al. Community-Acquired Pneumonia Incidence in Adults Aged
18 Years and Older in Goto City, Japan: A Prospective Population-Based Study. CHEST Pulmonary 2023;
1(2).
38